Eribulin Mesylate and Cisplatin in Treating Patients With Advanced Solid Tumors

National Cancer Institute (NCI)

Status and phase

Completed

Phase 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific

Treatments

Other: laboratory biomarker analysis

Drug: eribulin mesylate

Other: pharmacological study

Drug: cisplatin

Study type

Interventional

Funder types

NIH

Identifiers

NCT00415324

U01CA062505 (U.S. NIH Grant/Contract)

7427 (Other Identifier)

PHI-55

CDR0000518290

P30CA033572 (U.S. NIH Grant/Contract)

NCI-2009-00168 (Registry Identifier)

Details and patient eligibility

About

This trial is studying the side effects and best dose of eribulin mesylate and cisplatin in treating patients with advanced solid tumors.Drugs used in chemotherapy, such as eribulin mesylate and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.

Full description

Primary Objectives:

I. To determine the maximum tolerated dose of E7389 and cisplatin in patients with advanced solid tumors.

II. To determine the safety and toxicity of this regimen in these patients. III. To determine the pharmacokinetics of this regimen in these patients.

Outline: This is a multicenter, dose-escalation study. Patients receive eribulin mesylate IV over 5 minutes on days 1, 8, and 15 and cisplatin IV over 30-60 minutes on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed for up to 8 weeks.

Enrollment

36 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

Histologically confirmed malignant solid tumor
Advanced disease, meeting both of the following criteria: Metastatic or unresectable disease and standard curative or palliative measures do not exist or are no longer effective.
No known active brain metastases
Life expectancy > 3 months
ECOG performance status 0-2
Bilirubin normal
No uncontrolled intercurrent illness including, but not limited to, any of the following: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, psychiatric illness or social situation that would limit study compliance.
Negative pregnancy test
Fertile patients must use effective contraception
Recovered from prior therapy
No prior chemotherapy within the past 4 weeks (6 weeks for nitrosoureas or mitomycin C).
No prior targeted therapy within the past 4 weeks
No prior immunotherapy within the past 4 weeks
No prior radiotherapy within the past 4 weeks.
No more than 2 prior chemotherapy regimens for advanced solid tumors.
No other concurrent investigational agents. Bisphosphonate therapy (e.g., pamidronate or zolendronate) is not considered investigational therapy.
No concurrent antiretroviral therapy for HIV-positive patients.
No other concurrent anticancer agents or therapies.
Tumor has spread to other parts of the body or cannot be removed by surgery.
More than 4 weeks since chemotherapy, biological therapy, or radiation therapy.
No more than two previous chemotherapy regimens for advanced solid tumor.
WBC >= 3,000/mm^3
Platelet count >= 100,000/mm^3
Creatinine clearance >= 60 mL/min
Absolute neutrophil count >= 1,500/mm³
AST and ALT =< 2.5 times upper limit of normal
No prior cumulative cisplatin dose > 300 mg/m^2
No preexisting neuropathy <= grade 2
Not pregnant or nursing